Avastin's rise to dominance in AMD, the CATT trial, support for Avastin from the American Academy of Ophthalmology, beginnings of the repackaging controversy, U.K. authorities' influence on use of Lucentis and Avastin, the IVAN trial, Genentech's influence on Avastin repackaging, opposition to Genentech's distribution decision, Genentech revises its position.

The elimination of an allergy or adverse reaction could be the difference between success and failure in an ophthalmic procedure. We have the ability to compound preservative-free and additive-free preparations, including topical solutions and intraocular injections that save your patients from discomfort and speed recovery time. Examples of some preservative-free ophthalmics include: Triamcinolone Acetonide, Timolol, Prednisolone, Dexamethasone, etc.

Few innovations in medicine have been adopted throughout the world as rapidly as the off-label use of intravitreal Avastin. To date, the global ophthalmic community has found no evidence of ocular or systemic toxicity, and Avastin appears to be effective. However, the long term safety of intravitreal Avastin is still unknown and needs to be studied. Although most of the clinical experience to date is anecdotal, there is a growing belief that these early observations will be predictive of future success when intravitreal Avastin is studied prospectively.